Nasoryl (Xylometazoline Hydrochloride, Ipratropium Bromide)

• Nasoryl is indicated for the symptomatic relief of nasal congestion associated with several upper‑respiratory conditions, providing rapid decongestion.
• Allergic rhinitis: relieves nasal blockage, reduces mucosal swelling, and improves breathing in patients with allergic rhinitis.
• Common cold: alleviates nasal congestion, decreases excess mucus, and helps restore normal breathing during the common cold.
• Non‑allergic rhinitis: decreases glandular secretions and nasal swelling, enhancing airflow for individuals with non‑allergic rhinitis.

• Xylometazoline hydrochloride acts as an alpha‑adrenergic agonist on the α1‑ and α2‑receptors of nasal mucosal blood vessels, causing vasoconstriction and reduced edema. Ipratropium bromide is an antimuscarinic agent that blocks muscarinic receptors on nasal glandular epithelium, inhibiting acetylcholine‑mediated secretion. The combined actions decrease both vascular engorgement and mucus production, leading to improved nasal airflow. These effects begin within minutes and can last several hours, providing sustained relief during the day.

Nasoryl may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects

• Nasal irritation or burning sensation
• Dryness of the nasal mucosa
• Sneezing
• Headache
• Nasal crusting
• Taste disturbance
• Throat irritation

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis, angioedema)
• Persistent nasal bleeding (epistaxis)
• Vision changes
• Elevated intraocular pressure

Before using Nasoryl, consider the following precautions to ensure safe use.

• Indication: Use only for short‑term relief, typically not exceeding three consecutive days.
• Contraindication: Avoid in patients with known hypersensitivity to either active ingredient.
• Caution: Use with care in individuals with hypertension or cardiovascular disease.
• Pregnancy: Safety has not been established; consult a healthcare professional before use.
• Interaction: Do not combine with other nasal decongestants to prevent excessive vasoconstriction.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nasoryl can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertensive crisis when combined with alpha‑adrenergic agonists.
• Other intranasal vasoconstrictors (e.g., oxymetazoline): can cause excessive nasal vasoconstriction and rebound congestion.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs (e.g., atropine): additive anticholinergic effects may increase dryness.
• Beta‑blockers: may blunt systemic cardiovascular response to alpha‑agonist.
• Antihistamines: combined use may enhance drying of nasal mucosa.